Our Pricing

How Much Does Wegovy Cost Monthly? UK Price Guide

Understanding wegovy cost monthly uk is essential before starting treatment. At Cured Pharmacy, Wegovy (semaglutide) is available from £79.00 per month with transparent upfront pricing, free clinical assessment by UK prescribers, and discreet next-day delivery across the UK.

Wegovy Cost Monthly UK: What You'll Pay

Wegovy pricing in the UK depends on your prescribed dose, which increases gradually over 16-20 weeks as part of the licensed titration schedule. At Cured Pharmacy, monthly costs start from £79.00, with prices displayed transparently before your free consultation — no hidden fees or surprise charges after prescriber approval.

Your treatment begins at 0.25mg weekly for the first month, escalating through 0.5mg, 1mg, and 1.7mg before reaching the maintenance dose of 2.4mg weekly [1]. Each dose tier has a corresponding monthly cost, but you'll always see the exact price before proceeding with your clinical assessment by our UK-registered prescribers.

Unlike some providers who reveal pricing only after consultation, Cured Pharmacy guarantees the lowest prices in the UK with full transparency from your first visit. All Wegovy pens are genuine UK-licensed medications dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural gut hormone involved in appetite regulation and glucose metabolism. By activating GLP-1 receptors in the brain, pancreas, and digestive system, semaglutide reduces hunger signals, slows gastric emptying, and improves insulin sensitivity [2].

In the landmark STEP 1 trial involving 1,961 adults with obesity, participants using Wegovy 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. Approximately 86% of participants lost at least 5% of their baseline weight, and 50% achieved reductions exceeding 15% [2].

These results represent the most substantial weight loss outcomes demonstrated in clinical trials for any licensed obesity medication available in the UK. However, individual results vary, and Wegovy works best when combined with reduced-calorie nutrition and increased physical activity, as assessed by your UK prescriber during consultation.

What to Expect During Treatment

Most patients begin noticing appetite reduction within the first 2-4 weeks of treatment, though maximum weight loss typically occurs after reaching the 2.4mg maintenance dose around week 16-20. Your UK prescriber will monitor your progress and may adjust the titration schedule based on your tolerance and clinical response.

Common initial side effects include mild nausea, diarrhoea, and constipation, which generally diminish as your body adapts to each dose increase [3]. The gradual dose escalation protocol is specifically designed to minimise gastrointestinal symptoms while optimising efficacy.

Wegovy Dosing Schedule and Monthly Progression

The MHRA-approved Wegovy dosing protocol follows a structured 5-month escalation designed to optimise tolerability while achieving therapeutic effect. Understanding this schedule helps you plan the monthly cost progression throughout your treatment journey.

Month 1 begins with 0.25mg injected once weekly (four injections total). Month 2 increases to 0.5mg weekly. Month 3 advances to 1mg weekly, followed by 1.7mg weekly in month 4. From month 5 onwards, you'll maintain the target dose of 2.4mg weekly unless your prescriber recommends otherwise based on your individual response [1].

Each injection is self-administered subcutaneously using a pre-filled, single-dose pen. The pen design requires no manual dose selection — simply attach a new needle, dial to the single preset dose, and inject into your abdomen, thigh, or upper arm. Detailed instructions and video tutorials are provided with your first prescription.

What Happens If You Miss a Dose?

If you miss your weekly injection and fewer than 5 days have passed, administer the missed dose as soon as you remember, then resume your regular weekly schedule. If more than 5 days have elapsed, skip the missed dose entirely and take your next injection on the originally scheduled day [4].

Missing multiple consecutive doses may require restarting the titration schedule at a lower dose to avoid gastrointestinal side effects. Always consult your UK prescriber if you've missed more than two consecutive weekly injections before resuming treatment.

Wegovy vs Other Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each working through different mechanisms with varying efficacy profiles. Wegovy (semaglutide) is a once-weekly GLP-1 receptor agonist delivering substantial weight reduction in clinical trials, while alternatives include daily injectable options and dual-pathway treatments.

Saxenda (liraglutide) is an earlier GLP-1 medication requiring daily injections, with clinical trials showing average weight loss of 8% over 56 weeks — approximately half the reduction achieved with Wegovy [5]. The daily injection requirement and lower efficacy make Saxenda less convenient for many patients, though it remains a viable option for those who respond well to lower-intensity GLP-1 therapy.

Newer dual GIP/GLP-1 receptor agonists have demonstrated even greater weight loss than semaglutide in head-to-head trials, with some patients achieving reductions exceeding 20% of baseline weight [6]. Your UK prescriber will assess your medical history, weight loss goals, previous treatment responses, and budget to recommend the most appropriate option during your free consultation.

Oral medications like Orlistat and Mysimba work through entirely different mechanisms — Orlistat blocks fat absorption in the gut, while Mysimba combines naltrexone and bupropion to reduce cravings. These typically produce more modest weight loss (5-10%) but may suit patients who prefer tablets over injections or have contraindications to GLP-1 therapy.

Who Can Use Wegovy in the UK?

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [1]. Your UK prescriber will calculate your BMI and review your medical history during the online consultation to confirm eligibility.

Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), as GLP-1 receptor agonists caused thyroid C-cell tumours in rodent studies [4]. It's also not recommended during pregnancy or breastfeeding, or in patients with severe gastrointestinal disease including gastroparesis.

If you're currently taking other medications for diabetes, blood pressure, or cholesterol, inform your prescriber during assessment. Wegovy can affect the absorption and efficacy of oral medications due to delayed gastric emptying, and doses of concurrent diabetes medications may require adjustment to prevent hypoglycaemia [4].

Medical Conditions Requiring Extra Caution

Patients with a history of pancreatitis, severe kidney disease (eGFR <30 mL/min), or diabetic retinopathy require careful evaluation before starting Wegovy. Clinical trials reported rare cases of acute pancreatitis, and rapid weight loss may temporarily worsen diabetic eye disease in susceptible individuals [3][4].

Your UK prescriber will review your complete medical history, current medications, and recent blood test results if available. In some cases, baseline kidney function tests or HbA1c measurements may be recommended before initiating treatment, particularly if you have existing metabolic conditions.

How to Order Wegovy from Cured Pharmacy

Ordering Wegovy from Cured Pharmacy takes under 3 minutes through our streamlined online consultation process. Click 'Start Assessment' to complete a confidential medical questionnaire reviewed by a UK-registered prescriber, typically within 24 hours on weekdays.

If your prescriber approves Wegovy based on your medical history and weight loss goals, we'll dispense your prescription from our GPhC-registered pharmacy and dispatch via discreet next-day delivery across the UK. All packaging is plain and unmarked, with no external indication of contents, ensuring complete privacy.

Your first prescription will include the starter dose (0.25mg) with clear written and video instructions for self-administration. Follow-up prescriptions are easily reordered through your secure online account as you progress through the dose escalation schedule. Our clinical team remains available by phone (+44 116 4646009) throughout your treatment for any questions or concerns.

Cured Pharmacy guarantees the lowest Wegovy prices in the UK, with transparent costs displayed before consultation and no hidden fees. All medications are genuine UK-licensed products sourced directly from licensed wholesalers — we never supply unlicensed imports or compounded alternatives.

Ongoing Support and Monitoring

Weight loss treatment works best with regular monitoring and lifestyle modifications. Your UK prescriber may recommend follow-up consultations every 3-6 months to assess progress, review side effects, and adjust treatment as needed. Some patients achieve their target weight and successfully maintain it with reduced doses or eventual discontinuation.

NICE guidelines recommend considering treatment discontinuation if patients fail to lose at least 5% of baseline weight after 6 months at the maintenance dose, though individual circumstances vary [7]. Your prescriber will work with you to set realistic goals and determine the optimal treatment duration for your specific situation.

Scientific References

1. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy (semaglutide): Patient Information Leaflet. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
5. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
6. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). Retrieved from https://www.nice.org.uk/guidance/cg189
8. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.